Ausgabe 2/2009
Inhalt (8 Artikel)
The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia
- Clinical Trials Report
Hien K. Duong, Matt Kalaycio
Predicting the response of CML patients to tyrosine kinase inhibitor therapy
Deborah L. White, Timothy P. Hughes
Clinical implications of c-Kit mutations in acute myelogenous leukemia
Muriel Malaise, Daniel Steinbach, Selim Corbacioglu
MicroRNA expression in acute myeloid leukemia
Guido Marcucci, Michael D. Radmacher, Krzysztof Mrózek, Clara D. Bloomfield